Unlocking Generic Market Access: A Retrospective Analysis of USFDA Paragraph IV Filings (2020-2024)

Area of Science:

• Pharmaceutical economics
• Regulatory science
• Intellectual property law

Background:

• Paragraph IV (PIV) certification allows generic drug applications before patent expiry.
• Innovator patents and patent settlements significantly influence generic market entry timelines.
• Regulatory frameworks, including the FDA's processes and proposed legislation like the BLOCKING Act, shape pharmaceutical market dynamics.

Purpose of the Study:

• To analyze the impact of PIV certification on generic drug market entry.
• To examine challenges from patent settlements, the BLOCKING Act, and FDA decisions.
• To understand the balance between pharmaceutical innovation and drug accessibility.

Main Methods:

• Analysis of USFDA PIV certification lists and application statuses (2020-2024).
• Review of litigation trends among major generic manufacturers.
• Evaluation of the potential effects of the BLOCKING Act on exclusivity periods.

Main Results:

• Nearly 50% of PIV ANDA applications are 'Eligible,' with others deferred or extinguished.
• 2023 saw a peak in eligible ANDA submissions.
• Leading generic firms actively challenge patents, yet litigation delays market entry.

Conclusions:

• Patent litigation remains a primary obstacle to timely generic drug availability.
• The proposed BLOCKING Act could diminish the 180-day exclusivity incentive, reducing market entry predictability.
• FDA facilitates generic applications, but legal challenges significantly impact cost-effective drug access.